Posted by Michael Wonder on 11 Sep 2019
Decision for funding in the immunosuppressant, cardiovascular and anti-nausea therapeutic areas
11 September 2019 - PHARMAC pleased to announce a decision to approve proposals relating to medicines in the immunosuppressant, cardiovascular and anti-nausea therapeutic areas.
In summary, this will result in the following changes from 1 October 2019:
- Adalimumab (Humira) access will be widened to include treatment of hidradenitis suppurativa, a chronic inflammatory skin condition
- Nicardipine hydrochloride injection access will be widened in DHB hospitals to include use as an antihypertensive/vasodilator in adults
- Ondansetron dispersible tablets will be available on a Practitioner’s Supply Order for treatment of acute nausea and vomiting
